Suchergebnisse
IBRX Stock Slides on FDA Warning Over Misleading Cancer Drug Claims
Shares of ImmunityBio IBRX fell more than 21% on Tuesday after the FDA issued a warning letter over “false” or “misleading” promotional statements related to the company’s cancer drug Anktiva.
What
